|Bid||22.11 x 900|
|Ask||22.30 x 1400|
|Day's Range||22.11 - 22.80|
|52 Week Range||12.01 - 28.00|
|Beta (5Y Monthly)||1.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2021 - Aug 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.78|
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that Michael White, Ph.D., will join the company as its Chief Scientific Officer, effective November 1, 2021.
Michael P Dillon, SVP And Chief Scientific Officer at Ideaya Biosciences (NASDAQ:IDYA), made a large buy and sell of company shares on September 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 8, Michael P Dillon bought 11,500 Ideaya Biosciences shares at prices ranging from $4.31 to $11.08 per share, for a total of $78,764. They then sold their shares on succeeding transactions in the open market at pric
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in September 2021.